GRANULES vs NATCOPHARM: Stock Comparison

Granules India Limited vs Natco Pharma Limited

Live data: 28 July 2026, 4:08 PM IST • Source: NSE and company filings

Granules India Limited is the larger company by market capitalisation. Granules India Limited shows faster revenue growth, while Natco Pharma Limited shows a lower P/E, a higher ROE and a higher dividend yield. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Granules India Limited and Natco Pharma Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, GRANULES is more favourable on 4 of 13 scored metrics and NATCOPHARM on 9These counts are context-free and are not an overall rating.

Key Differences

Market Cap
GRANULES is the larger company
₹20,831 Cr vs ₹16,536 Cr
P/E Ratio
NATCOPHARM has a lower P/E
11.68x vs 31.29x
P/B Ratio
NATCOPHARM has a lower P/B
1.8x vs 4.11x
EPS
NATCOPHARM has higher earnings per share
₹79.24 vs ₹26.92
Dividend Yield
NATCOPHARM has a higher dividend yield
0.52% vs 0.21%
Revenue Growth (TTM YoY)
GRANULES has faster revenue growth
22.8% vs -39.6%
EPS Growth (TTM YoY)
GRANULES has faster EPS growth
31.3% vs -34.1%
Qtr Sales Growth
GRANULES has stronger quarterly sales growth
22.8% vs -39.5%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricGRANULESNATCOPHARM
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricGRANULESNATCOPHARM
Live Price₹845.4₹925.05
Day Change0.31%-0.22%
Volume7.05 L1.52 L
52-Week High₹910₹1,226.8
52-Week Low₹432.6₹789
Distance from 52W High-7.1%-24.6%

Valuation

MetricGRANULESNATCOPHARM
Market Cap₹20,831 Cr₹16,536 Cr
P/E Ratio31.29x11.68x
P/B Ratio4.11x1.8x
EPS₹26.92₹79.24
Book Value₹205.21₹514.92
Dividend Yield0.21%0.52%

Growth

MetricGRANULESNATCOPHARM
Revenue Growth (TTM YoY)22.8%-39.6%
EPS Growth (TTM YoY)31.3%-34.1%
Qtr Sales Growth22.8%-39.5%
Qtr Profit Growth44.6%-34.1%

Profitability & Leverage

MetricGRANULESNATCOPHARM
ROE13.7%16.9%
ROCE15.5%17.1%
Net Margin11.15%34.78%
Operating Margin22.1%35.2%
Debt to Equity0.3x0.08x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricGRANULESNATCOPHARM
Promoter Holding37.67%49.14%
FII Holding17.5% 2.19 pp16.99% 0.38 pp
DII Holding16.11% 0.9 pp5.62% 0.16 pp
Public Holding28.38% 1.28 pp27.97% 0.22 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Granules India Limited and Natco Pharma Limited.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.